# Tyra Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Tyra Biosciences, Inc.). ## Overview Tyra Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on precision medicines for oncology and genetically defined conditions. Its pipeline centers on oral small-molecule programs that target fibroblast growth factor receptor (FGFR) biology, including dabogratinib and TYRA-200, supported by its proprietary SNÅP drug-design platform. ## Products & services • Oral dabogratinib (formerly TYRA-300) • TYRA-200 (SURF201) • TYRA-430 (SURF431) • SNÅP precision medicine discovery platform • Preclinical FGFR-focused oncology programs - **Clinical-stage drug candidates** (0%) — Oral small-molecule programs in clinical development for FGFR-driven cancers and related conditions. - **Discovery platform** (0%) — SNÅP is the internal drug-design platform used to generate and optimize new candidates. - **Preclinical pipeline** (0%) — Undisclosed early-stage programs focused on FGFR biology and other precision-oncology targets. - Oral dabogratinib (formerly TYRA-300) - TYRA-200 (SURF201) - TYRA-430 (SURF431) - SNÅP precision medicine discovery platform - Preclinical FGFR-focused oncology programs ## Customers Tyra Biosciences does not currently sell commercial products; its near-term 'customers' are clinical trial participants, investigators, and research sites that support development of its drug candidates. If approved in the future, its products would be used by oncology and specialty-care physicians treating FGFR-driven cancers and genetic conditions. - **Clinical trial patients** (primary) — Patients with FGFR-altered cancers or genetic conditions enrolled in studies of TYRA-200, TYRA-430, and dabogratinib. - **Clinical investigators and trial sites** (primary) — Hospitals and research centers that recruit patients, administer study drugs, and generate safety/efficacy data. - **Future oncology prescribers** (secondary) — Oncologists who would prescribe approved FGFR-targeted therapies for urothelial cancer, ICC, HCC, and other tumors. - **Future specialty-care physicians** (secondary) — Physicians treating skeletal dysplasia who could use dabogratinib if it reaches that indication. - Clinical trial patients enrolled in TYRA-200 and TYRA-430 studies - Investigators and trial sites running multicenter oncology studies - Future oncology prescribers treating FGFR-altered cancers - Future specialty physicians treating skeletal dysplasia - Potential future partners or licensees for commercialization ## Geography Tyra Biosciences is headquartered in the United States and conducts development work through a clinical-trial network that can span multiple countries. Its business is geographically driven by where patients can be enrolled, where regulators approve trials, and where future commercialization partners may operate. - Headquartered in the United States - Clinical development is run through multicenter trial sites - Trial geography can expand with patient-enrollment needs - Future commercialization would depend on major market approvals - Potential manufacturing and supply-chain exposure may include China ## Strategy Tyra Biosciences is building a wholly owned pipeline around FGFR biology, using its SNÅP platform to design more selective oral candidates with the goal of improving potency, tolerability, and resistance coverage. Its strategy is to advance lead programs in FGFR3- and FGFR4-related disease settings while extending the platform into additional precision-oncology targets. - **Advance lead clinical programs** (short-term) — Clinical proof-of-concept is the main value driver for a pre-revenue biotech. - **Differentiate through selectivity and resistance coverage** (medium-term) — Better selectivity and resistance handling can improve efficacy and tolerability versus older FGFR drugs. - **Expand the SNÅP discovery engine** (long-term) — A productive platform can create multiple shots on goal beyond the current pipeline. - Advance dabogratinib across FGFR3-driven cancers and skeletal dysplasia - Develop TYRA-200 for acquired resistance in intrahepatic cholangiocarcinoma - Progress TYRA-430 in FGFR4/FGFR3-driven liver and solid tumors - Use SNÅP to generate new oral small-molecule candidates - Build data packages that support future partnering or approval ## Risks Tyra Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and the possibility that its candidates never reach commercialization. It also depends on third-party manufacturers and clinical infrastructure, which creates supply-chain, execution, and geopolitical exposure, including potential reliance on China-based contract manufacturers. - **Clinical development failure** [critical] — The company has no approved products, so value depends on positive trial readouts and tolerability. - **Regulatory and approval risk** [high] — Even promising data may not translate into marketing approval or label breadth. - **Competitive displacement** [high] — Other FGFR and oncology therapies may be more effective, safer, or faster to market. - **Third-party manufacturing and CRO dependence** [medium] — The company relies on external partners for clinical supply and trial execution. - **China sourcing and trade restrictions** [medium] — Use of foreign contract manufacturers can be affected by tariffs, sanctions, and U.S. restrictions. - Clinical trials may fail to show safety or efficacy - Regulatory approval may take longer or never occur - Competition from larger oncology drug developers is intense - Dependence on third-party manufacturers and CROs - Potential exposure to China-based supply-chain restrictions ## Accounting As a pre-revenue biotech, Tyra Biosciences' reported results are driven mainly by research and development expense accruals, clinical trial spending, and non-cash fair-value or stock-based compensation items. Investors should watch how management estimates accrued R&D costs, because timing differences between vendor invoices and trial activity can shift quarterly expense recognition. - **Accrued research and development expenses** — Can move quarterly operating expense and liabilities - **Stock-based compensation** — Affects operating loss and equity dilution - **Marketable securities valuation and interest income** — Affects other income and liquidity presentation - Accrued R&D estimates affect quarterly expense timing - Clinical trial and CRO costs can be recognized before invoicing - Stock-based compensation can materially affect operating loss - Cash, cash equivalents, and marketable securities are key liquidity items - No revenue recognition complexity yet because no products are commercialized --- *Last updated: 2026-04-29T05:04:54.162989+00:00*